Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma.
about
Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myelomaInterpretation of cytogenetic results in multiple myeloma for clinical practiceChromosome translocations in multiple myelomaC-MAF oncogene dysregulation in multiple myeloma: frequency and biological relevanceFrequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3Deregulation of the carbohydrate (chondroitin 4) sulfotransferase 11 (CHST11) gene in a B-cell chronic lymphocytic leukemia with a t(12;14)(q23;q32)A B-cell-specific DNA recombination complexTranscriptional repression of Bim by a novel YY1-RelA complex is essential for the survival and growth of Multiple MyelomaDeregulation of c-Myc Confers distinct survival requirements for memory B cells, plasma cells, and their progenitorsDetection of illegitimate rearrangement within the immunoglobulin locus on 14q32.3 in B-cell malignancies using end-sequenced probes.Rapid detection of IgH/BCL2 rearrangement in follicular lymphoma by interphase fluorescence in situ hybridization with bacterial artificial chromosome probes.An unusual H-Ras mutant isolated from a human multiple myeloma line leads to transformation and factor-independent cell growth.Trans-chromosomal recombination within the Ig heavy chain switch region in B lymphocytes.Endothelial progenitor cells display clonal restriction in multiple myeloma.In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes.Translocation t(6;14) as the sole chromosomal abnormality in adenoid cystic carcinoma of the base of tongue.Molecular analysis of immunoglobulin genes in multiple myeloma.Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.The rise and fall of long-lived humoral immunity: terminal differentiation of plasma cells in health and disease.DNA methylation changes and multiple myeloma.Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma.Determinants of sensitivity to DZNep induced apoptosis in multiple myeloma cells.Multiple myeloma--evolving concepts of biology and treatment.Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma.A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.Lymphoid malignancies: the dark side of B-cell differentiation.The presence of circulating clonal CD19+ cells in multiple myeloma.Protein ubiquitination in lymphoid malignancies.Isotype class switching and the pathogenesis of multiple myeloma.Chromosomal and genetic abnormalities in myeloma.Ectopic expression of wild-type FGFR3 cooperates with MYC to accelerate development of B-cell lineage neoplasms.Translocation of an antibody transgene requires AID and occurs by interchromosomal switching to all switch regions except the mu switch region.In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cellsMonoclonal gammopathies of undetermined significance: a review.Genetics of multiple myeloma: another heterogeneity level?Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cellsRapid high-resolution mapping of balanced chromosomal rearrangements on tiling CGH arrays.Many and multiple myeloma(s).Retroviruses hijack chromatin loops to drive oncogene expression and highlight the chromatin architecture around proto-oncogenic loci.Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14).
P2860
Q54749908-FFDE24EB-97D2-4082-9D8A-EB4B93DE270EQ54750449-2C9C8E95-7362-4418-A8F6-5ACC5A264486Q54830967-99BC2109-DB3B-4E1B-82FA-4B9E31AAE959Q54834976-F144368E-F575-4809-87AE-BA960C62BECFQ54898926-53D6A7F2-7568-41EA-A9AC-D47C27424439Q54898954-2105D71B-1D42-455F-9A32-36328683A894Q54900126-97683392-1809-4235-BEA2-46C2C4E4AD6AQ54900162-B1982F5F-35E1-4893-B2EC-6CD9CD2D97B6Q54906021-86858441-2F90-457E-A011-F51373A5510AQ54906030-AB3261F6-8972-46FE-8DA3-176A241D12C2Q54907771-49F24521-6E9C-4C32-AB6C-3EFF9BEA9113Q54908142-7E6CFB31-B135-44FD-B0EC-CEB62698A614Q54931788-C2D8039D-99F7-46BC-8213-011139AF46C4Q54936482-98FB712D-A6EF-4115-9718-63BEEB08842EQ54951245-1F5BC086-3E38-4E5B-92B3-DA3567E7EC9BQ54954407-8821941C-0ABC-45E2-8B9D-3F0FB79CE228Q54954410-56FC3A18-3F7E-46CD-BA8D-01773248079FQ54972277-B6258F70-37A8-43E7-B3D1-DBA5B5F635BFQ54973634-791F800F-CC69-4AF6-B6EB-ACCC4C8A10EBQ54992240-A80F6F6D-21AA-4258-A20E-5DCE89A22623
P1343
Q24619589-A7B75719-2F73-4680-A651-80ECF437D507Q26777803-B5BE2766-BBF2-42FC-800E-FA8CE776CA38Q28199347-D531623E-64D9-4369-A118-346576F971FAQ28235799-E42310CA-7FF5-4E38-BEC6-DCD029F8BD9DQ28242697-8667BCF6-29D4-48CB-A44D-0FF6624C7C6FQ28273746-C6AE5972-84B6-451F-A47C-5ECCE17B4E5BQ28274822-A6A5FDC9-7325-4D72-9BCE-E1168E283093Q28534603-250F24EA-60C4-46FB-9AB1-2603EE399D04Q30436741-920011B4-925B-4596-9F2B-00DFE9971654Q30727143-38BE8633-4D62-4FF6-AC26-E68171874509Q30841904-A6B80AAD-4F1E-487E-8DC3-C38097C3B9C9Q30885275-71D4D8F9-B738-46C1-BC2F-C10136E279CBQ32015309-BCC210D8-00D5-4652-91D0-A0D3BEB325C0Q33247497-41B12784-FA0C-423B-8EAB-03566FB24743Q33590961-55260EDB-14E2-4C57-92F1-FC9467EF6EF1Q33594753-14D99BD7-3B58-4B30-BFB8-019376EE0E5DQ33604355-3BE6313E-4183-4589-8E82-0D01B936F1F9Q33627051-6560F7D3-DE61-4BF9-B924-4C5DDCED0CB0Q33685257-C6B7BC35-EF6F-4BAB-82E7-78F4D5C1344FQ33735188-1A219FB7-84B5-42B5-BBFD-943239A20860Q33846310-7DFBEA63-0A7E-4962-8BCB-808BD11CBF38Q33948015-3C9A2D78-C28C-4ECF-A231-B2F82A772777Q33983634-1E26FA42-B489-4C0C-806E-C52D8E6A671DQ34020965-F84A4B06-1C96-4BEC-8AD8-FA628099050CQ34134986-7AEC8926-7984-467D-A4C7-EBB385275DA5Q34162187-5B56A90A-5300-4D60-A783-0726B15CFFF3Q34575627-2D3E8739-A4A7-4B31-A3F5-F158D2A90E42Q34722684-0EAD3DF4-DDA7-439F-AA84-19416D514359Q34733051-E1C24A6C-56F5-4F4F-AA2A-76D5B3D80D56Q34929064-D924DDF1-06E9-408F-ADFD-46A3E9F77E25Q35055386-71FDB5FC-16E3-48E8-AAC4-FFFACAEF51B9Q35124628-8F891446-77D4-4E0B-890D-A9441D736F31Q35167162-B598DE1E-1805-4325-826D-0CFC4AFCB75AQ35170927-B0EB5002-4757-49D6-8527-F9FB273F4F76Q35197437-49D27E09-FE97-443A-BC51-B5D66023ED3CQ35337908-D1D06333-CEB6-4916-B956-948C2328F3A6Q35356418-B4B33555-AA33-46EE-ADF6-CCA6C757EE4DQ35545068-36CAFED0-9CD3-4F75-924D-9A91FD55FBCDQ35584064-10495427-1B4F-4BF8-A1F9-4ABE543574B5Q35810205-27C43CB4-38F1-45FB-BCAA-7E8DB2DD030A
P2860
Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Promiscuous translocations int ...... h regions in multiple myeloma.
@ast
Promiscuous translocations int ...... h regions in multiple myeloma.
@en
type
label
Promiscuous translocations int ...... h regions in multiple myeloma.
@ast
Promiscuous translocations int ...... h regions in multiple myeloma.
@en
prefLabel
Promiscuous translocations int ...... h regions in multiple myeloma.
@ast
Promiscuous translocations int ...... h regions in multiple myeloma.
@en
P2093
P2860
P4510
P356
P1476
Promiscuous translocations int ...... h regions in multiple myeloma.
@en
P2093
P2860
P304
13931-13936
P356
10.1073/PNAS.93.24.13931
P407
P577
1996-11-01T00:00:00Z